Could the patient's symptoms be due to coronary vasospasm rather than myocardial ischemia from a coronary steal phenomenon?

Coronary Vasospasm vs Myocardial Ischemia from Steal Phenomenon

Both coronary vasospasm and steal phenomenon can cause myocardial ischemia, but they are distinct mechanisms that require different diagnostic approaches and treatments—vasospasm involves dynamic epicardial or microvascular constriction (>90% reduction in diameter) that responds to nitrates and calcium channel blockers, while steal phenomenon involves fixed anatomic shunting of blood away from myocardium, typically not responsive to vasodilators.

Distinguishing Features

Coronary Vasospasm Characteristics

Clinical presentation:

• Chest pain typically occurs at rest, particularly in early morning hours (circadian pattern) 1, 2, 1, 2
• Episodes occur in clusters with asymptomatic periods lasting weeks to months 1, 2
• Pain is exquisitely responsive to nitroglycerin 1, 2
• May be precipitated by emotional stress, hyperventilation, exercise, or cold exposure 1, 2
• Smoking is the most consistent risk factor (more so than traditional atherosclerotic risk factors) 1, 2, 3

ECG findings:

• Transient ST-segment elevation during pain episodes is the hallmark 1, 2
• ST-depression can also occur (one-third of patients) 1
• Changes resolve when chest discomfort abates 2

Diagnostic confirmation: The 2023 AHA/ACC guidelines define "definitive" vasospastic angina as: nitrate-responsive angina with either transient ischemic ECG changes during spontaneous episodes OR fulfillment of coronary artery spasm criteria (>90% constriction with angina and ischemic ECG changes) 4.

Steal Phenomenon Characteristics

Steal phenomenon involves:

• Fixed anatomic abnormality (e.g., coronary fistula, anomalous coronary origin)
• Symptoms typically provoked by exertion (increased demand unmasks inadequate perfusion)
• Poor or absent response to nitrates (may worsen symptoms by dilating the "stealing" vessel)
• Continuous rather than episodic pattern

Diagnostic Algorithm

Step 1: Initial Assessment

• Document timing of symptoms (rest vs exertion, time of day)
• Assess nitroglycerin response (rapid relief suggests vasospasm)
• Review risk factors (smoking strongly suggests vasospasm; congenital anomalies suggest steal)
• Obtain 12-lead ECG during pain (ST-elevation = vasospasm until proven otherwise)

Step 2: Non-invasive Testing

• 24-hour ambulatory ECG monitoring to capture ST-segment changes during spontaneous pain episodes 1, 2
• Exercise testing may show variable results in vasospasm (ST-elevation, ST-depression, or no change in roughly equal thirds) 1
• Echocardiography or nuclear imaging during pain can document transmural ischemia 1, 2

Step 3: Invasive Coronary Function Testing

The 2024 ESC guidelines provide a Class I recommendation for availability of invasive coronary function testing at initial angiography when mechanisms are uncertain 5, 6.

For suspected vasospasm:

• Provocative testing with intracoronary acetylcholine is now the preferred method 4, 1, 7
• Epicardial spasm = >90% reduction in coronary diameter after acetylcholine compared to baseline (after nitroglycerin) with symptoms and ST-segment deviation 4, 6
• Microvascular spasm = angina during acetylcholine with ischemic ST-changes but <90% epicardial constriction 4
• Important caveat: Catheter-induced spasm is NOT diagnostic of vasospastic disease 1

For suspected steal:

• Angiography demonstrates fixed anatomic shunting (fistula, anomalous vessel)
• Flow measurements show diversion of blood away from myocardium
• No response to intracoronary nitroglycerin

Critical Pitfalls

1. Beta-blockers in vasospasm: Have theoretical adverse potential through unopposed alpha-adrenergic vasoconstriction and should be avoided or used cautiously 1, 2, 7, 2, 8

2. Provocative testing contraindications: Should NOT be performed in patients with significant left main disease, advanced 3-vessel disease, high-grade obstructive lesions, significant valvular stenosis, or severe LV dysfunction 7

3. Vasospasm can coexist with atherosclerosis: 39% have single-vessel disease and 19% have multivessel disease 1, 2—don't exclude vasospasm based on presence of plaques

4. Microvascular vs epicardial spasm: Both exist and require invasive testing to distinguish; microvascular spasm may be missed without acetylcholine provocation 4, 6

Treatment Implications

For Confirmed Vasospasm 4, 1, 2, 7, 2:

First-line therapy:

• Calcium channel blockers in moderate-to-high doses (verapamil 240-480 mg/day, diltiazem 180-360 mg/day, or nifedipine 60-120 mg/day)
• Long-acting nitrates
• Sublingual nitroglycerin as needed
• Mandatory smoking cessation

For refractory cases:

• Combine nitrates with two calcium channel blockers of different classes (dihydropyridine + verapamil or diltiazem)
• Consider alpha-receptor blockers 1, 2

Avoid:

• Beta-blockers (controversial, theoretical harm)

For Steal Phenomenon:

• Medical therapy typically ineffective
• Surgical or percutaneous closure of fistula/shunt often required
• Vasodilators may worsen steal

Prognosis Considerations

Vasospastic angina prognosis depends on underlying coronary anatomy 2, 9:

• Normal/near-normal arteries: 95% 5-year survival
• Single-vessel disease: 95% 5-year survival
• Multivessel disease: 80% 5-year survival
• Complications include MI (6.5% at 7 years), sudden death (3.6%), high-degree AV block, and ventricular arrhythmias 2

The 2024 Canadian guidelines emphasize that vasospasm accounts for a significant proportion of MINOCA cases and requires mechanism-specific diagnosis and treatment 10.